Stage IVC Squamous Cell Carcinoma of the Oropharynx Completed Phase 2 Trials for Bortezomib (DB00188)

IndicationStatusPhase
DBCOND0029839 (Stage IVC Squamous Cell Carcinoma of the Oropharynx)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00103259Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckTreatment